Abstract:It is well known that epithelial-mesenchymal transition (EMT) can confer cancer cells with invasive and migratory capabilities associated with distant metastasis. As a key upstream factor in the Hippo pathway, Kibra (wwc1 gene) has been shown to suppress EMT in breast cancer cells, and we have found that its expression is reduced or lost completely in both human breast cancer cell lines and clinical tissue samples, particularly in triple negative breast cancer (TNBC). Unfortunately, the molecular mechanisms underlying this progression-associated event remain to be elucidated. Epigenetic gene silencing is one of the most common causes of suppressed expression of tumor suppressor genes. Furthermore, recent studies have demonstrated that EZH2 can recruit DNA methyltransferases, resulting in DNA methylation and subsequent gene silencing in certain circumstances. Thus, we hypothesized that there may exist a link between EZH2 and DNA methylation in association with wwc1 silencing in breast cancer. To test this hypothesis, we performed bisulfite sequencing, shRNA, co-IP, ChIP, MeDIP and ChIP-qPCR. As expected, RG108 or 5-Aza treatment improved the wwc1 gene transcription and Kibra protein expression. Both bisulfite sequencing and MeDIP demonstrated higher CpG methylation of the wwc1 promoter the TNBC cells (MDA-MB-231) than in luminal breast cancer cells (MCF7). It is noteworthy that ChIP and co-IP assays showed that EZH2, H3K27me3 and DNMT1 are enriched at the wwc1 promoter, and there exist physiologically relevant protein-protein interactions between them. We also found that EZH2 knockdown leads to a partial increase in Kibra expression and a considerable reduction in H3K27 and DNMT1 trimethylation. Moreover, ChIP-qPCR revealed more DNA fragments containing the wwc1 promoter in MDA-MB-231 than in MCF7 cells after immunoprecipitation with EZH2, DNMT1 and H3K27me3 antibodies. Collectively, our results reveal crosstalk between H3K27me3 inhibition catalyzed by EZH2 and CpG island methylation mediated by DNMT1 within the wwc1 promoter, which synergistically silence wwc1 gene expression in TNBC. Based on these results, we conclude that EZH2 shows promise as a potential anti-tumor target.

Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells.

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis

Integrative Analysis Reveals the Transcriptional Collaboration Between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression

Ezh2-Mediated Repression Of Gsk-3 Beta And Tp53 Promotes Wnt/Beta-Catenin Signaling-Dependent Cell Expansion In Cervical Carcinoma

EZH2-mediated Repression of GSK-3β and TP53 Promotes Wnt/β-catenin Signaling-Dependent Cell Expansion in Cervical Carcinoma.

Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4

The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells

EZH2 Gene and Cancer

EZH2 Mediated Metabolic Rewiring Promotes Tumor Growth Independently of Histone Methyltransferase Activity in Ovarian Cancer.

The roles of EZH2 in cancer and its inhibitors

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Enhancer of zeste homolog 2: A potential target for tumor therapy.

EZH2 is involved in silencing of WNT5A during epithelial–mesenchymal transition of colon cancer cell line

EZH1/2 as targets for cancer therapy

Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells is Polycomb-Independent

A Partially Disordered Region Connects Gene Repression and Activation Functions of EZH2

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

Oncogenic Functions of the EMT-related Transcription Factor ZEB1 in Breast Cancer

Polycomb Group Protein EZH2-mediated E-cadherin Repression Promotes Metastasis of Oral Tongue Squamous Cell Carcinoma.